<DOC>
	<DOCNO>NCT01457144</DOCNO>
	<brief_summary>Study First line mantle cell lymphoma treatment Rituximab , Velcade , Bendamustine Dexamethasone schema patient older 65 year 18 65 year old refuse receive conditioning regimen follow autograft .</brief_summary>
	<brief_title>Study Mantle Cell Lymphoma Treatment RiBVD</brief_title>
	<detailed_description>Demonstration Improvement progression-free survival ( PFS ) compare literature data . 6 month prolongation equal 24 month compare 18 month obtain whatever current regimen particular compare RCHOP regimen</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>mantle cell Lymphoma CD20 positive Untreated patient 65 an year old patient 18 65 year old patient ca n't refuse receive condition regimen follow autograft . Stages Ann Arbor II , III IV , ECOG performance status 0 , 1 2 Without history neoplasm , except situ cervix carcinoma cutaneous basal cell epithelioma , complete remission since 3 year , Without drug contraindication use schema ( Rituximab , bendamustine , Velcade , Dexamethasone ) , Without heart insufficiency stabilize , With follow biological value limit except pathological value due Medullary invading hypersplenism , hepatic involvement ) : PNN 1 G/L , Platelets 50 G/L , Transaminases ( SGOT SGPT ) alkalin phosphatases alcalines less 4 x normal , Bilirubin le 3 x N , Clearance creatinemia 20 mL/min Hepatitis B negative serology unless seropositivity clearly link vaccination . Can regularly follow Who sign informed consent , Affiliated national insurance scheme . Other type lymphoma mantle cell lymphoma accord OMS 2008 classification Patients relapse , except relapse due localize stade receive locoregional irradiation splenectomized , Central nervous system localization particular meninge , Drug use schema contraindication Rituximab , Bendamustine , VelcadeÂ® Dexamethasone Non stable diabetes , HIV positive active hepatitis C B ECOG performance status equal 3 Peripheral neuropathy , whatever origin , rat 2 NCI Non stabilize heart insufficiency , Patient ca n't receive hyperhydration order treat tumoral lysis syndrome prophylaxis , Patient ca n't , whatever reason , regularly follow , Major patient legal protection , ca n't give consent Patient sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>bendamustine</keyword>
	<keyword>Velcade</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>